SUBJECT: Cytotoxic Drug Permeation testing of KIMTECH* gloves Dear Valued Customer, Thank you for your enquiry about our gloves and their use for protection against chemical splash hazards by cytotoxic drugs. We must caution that the selection of the most appropriate glove for a specific task should be carried out by a trained safety professional following a ful risk assessment. It is Kimberly- Clark’s intent to provide data which can enable trained professionals to make an informed choice.
This letter contains the results of chemical permeation testing of cytotoxic drugs, performed on the fol owing gloves only:
KIMTECH PURE* G3 Sterile White Nitrile gloves
KIMTECH PURE* G3 Sterile STERLING* NITRILE gloves
KIMTECH PURE* G3 STERLING* NITRILE gloves
KIMTECH PURE* G5 STERLING* NITRILE gloves
KIMTECH SCIENCE* STERLING* NITRILE gloves and STERLING* NITRILE-XTRA gloves
KIMTECH SCIENCE* PURPLE NITRILE* gloves and PURPLE NITRILE-XTRA* gloves.
The fol owing test standards are referenced in this letter:
- EN374-3:2003 (Protective gloves against chemicals and micro-organisms; Part 3: Test for
determination of resistance to permeation by chemicals)
- ASTM D 6978-05 (Standard practice for assessment of resistance of medical gloves to permeation by
KIMTECH PURE* G3 Sterile White Nitrile gloves were tested according to EN374-3:2003, adapted with a reduction in swatch area chamber size, making it possible to use much smal er amounts of the toxic donor solution compared to the standard method. Results:
Drug and Concentration
Tests were carried out by an independent laboratory, under laboratory test conditions. These tests may not adequately replicate any specific condition of use, and because KIMBERLY-CLARK has no detailed knowledge or control over the conditions of end use, any of these data must be advisory only, and KIMBERLY-CLARK must decline any liability.
KIMTECH PURE* G3 Sterile STERLING* NITRILE gloves were tested according to ASTM D 6978-05 Standard Test Method for Resistance of Protective Clothing materials to Permeation by Liquids or Gases under Conditions of Continuous Contact. Results:
Drug and Concentration Breakthrough time
Tests were carried out by an independent laboratory, under laboratory test conditions. These tests may not adequately replicate any specific condition of use, and because KIMBERLY-CLARK has no detailed knowledge or control over the conditions of end use, any of these data must be advisory only, and KIMBERLY-CLARK must decline any liability.
Warning: Do not use this glove when there is a risk of exposure to splash hazards by Carmustine and Thiotepa. KIMTECH PURE* G3 STERLING* NITRILE gloves, KIMTECH PURE* G5 STERLING* NITRILE gloves, KIMTECH SCIENCE* STERLING* NITRILE gloves and KIMTECH SCIENCE* STERLING* NITRILE-XTRA gloves, are made from the same formulation, processing techniques as KIMBERLY-CLARK* STERLING* Nitrile gloves, were tested according to ASTM D 6978-05. Results:
Drug and Concentration Breakthrough time
Tests were carried out by an independent laboratory, under laboratory test conditions. These tests may not adequately replicate any specific condition of use, and because KIMBERLY-CLARK has no detailed knowledge or control over the conditions of end use, any of these data must be advisory only, and KIMBERLY-CLARK must decline any liability.
Warning: Do not use this glove when there is a risk of exposure to splash hazards by Carmustine and Thiotepa.
KIMTECH SCIENCE* PURPLE NITRILE* gloves and KIMTECH SCIENCE* PURPLE NITRILE-XTRA* gloves, are made from the same formulation, processing techniques as KIMBERLY-CLARK* PURPLE NITRILE* gloves, were tested according to ASTM D 6978-05. Results:
Drug and Concentration Breakthrough time
Tests were carried out by an independent laboratory, under laboratory test conditions. These tests may not adequately replicate any specific condition of use, and because KIMBERLY-CLARK has no detailed knowledge or control over the conditions of end use, any of these data must be advisory only, and KIMBERLY-CLARK must decline any liability.
Warning: Do not use this glove when there is a risk of exposure to splash hazards by Carmustine and Thiotepa.
We hope this information has been helpful. If we can assist further please let us know at [email protected] Regards
Jaime Cassar KIMBERLY-CLARK Category Manager EMEA - KIMTECH*
Fachinformation des Arzneimittel-Kompendium der Schweiz® Wirkstoff: Esomeprazolum ut Natrii esomeprazolum. Hilfsstoffe: Natrii edetas, Natrii hydroxidum. Galenische Form und Wirkstoffmenge pro EinheitPulver zur Herstellung einer Injektions- oder Infusionslösung. Trockenampulle (Durchstechflasche) zu 42,5 mg Natrii esomeprazolum (äquivalent zu 40 mg Esomeprazol). Indikationen/Anwendungsmöglic
WISSEN AKTUELL Kombinationstherapie: Bei wem, wann und womit? «Zielwerte erreichen bei Hypertonie – Neue Datenlage und Kon- nie-Experte zu bedenken. Mangelnde Compliance war zuvor auch zepte»: An der dritten Ausgabe der Swiss-Medicine-Arena® vom von den Teilnehmern der Swiss-Medicine-Arena in der vor Ort 17. Juni 2011 diskutierten Prof. Dr. med. Paul Erne, Chefarzt durchgef�